ABBV-RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV® AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for...
Data from a phase 1/2a study show RGX-314, a gene therapy from RegenX, was well tolerated and improved visual acuity in patients. Jeffrey Heier, MD With presentations on RGX-314 and ADVM-022 headlining the late breaking session, gene therapy was a hot topic on the first day of the ...
RGX-314 is designed as a single gene therapy intervention utilizing an adeno-associated virus 8 (AAV8) vector, to deliver an anti-VEGF fab transgene, potentially producing continuous anti-VEGF therapy in the eye. Initial data from the AAVIATE trial has provided encouraging evidence of RGX-314 ...
参考资料 [1] Regenxbio’s wet AMD gene therapy shows promise in phase 1. Retrieved Aug 8, 2018, from https://www.fiercebiotech.com/biotech/regenxbio-s-wet-amd-gene-therapy-shows-promise-phase-1 [2] REGENXBIO. Retrieved Aug 8, 2018, from https://regenxbio.gcs-web.com/news-release...
M.D., Chief Medical Officer of REGENXBIO. "Wet AMD is a leading cause of irreversible blindness and visual impairment in the world. We continue to be encouraged by the positive interim data for RGX-314 and the potential of NAV®AAV8 gene therapy as a one-time treatment for ...
简要标题 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD 临床分期 Phase 3 招募状态 Recruiting 首次公开日期 2022-06-07 条件/疾病 nAMD | CNV | Wet Age-related Macular Degeneration | AMD | WetAMD | wAMD 干预/治疗 RGX-314 Dose 1 | Aflibercept (EYLEA®) | RGX-314 Dose...
being evaluated, including a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. REGENXBIO has licensed certain exclusive rights to the SCS Microinjector®from Clearside Biomedi...
Safety of the Subretinal Delivery of RGX-314 AAV8-anti-VEGF Fab Gene Therapy in NHP: Retinal Structure Over One Year Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy, the mechanisms underlying dose-dependent retinal i... Bote,Erin,Lyubarsky,....
RGX-314 one-time gene therapy for diabetic retinopathy shows promise in phase 2 studyCimberle, MichelaOcular Surgery News
RGX-314 is designed as a single gene therapy intervention utilizing the NAV AAV8 vector to deliver a soluble anti-VEGF fab transgene to potentially provide continuous anti-VEGF therapy. This study will evaluate RGX-314 for the treatment of DR without center-involved diabetic macular edema (CI-...